Core Insights - Tonix Pharmaceuticals achieved FDA approval and launched TONMYA, the first new medicine for fibromyalgia in over 15 years, with over 1,500 healthcare providers prescribing it to approximately 2,500 patients by February 27, 2026 [2][4] - The company reported a net product revenue of approximately $13.1 million for the full year 2025, an increase from $10.1 million in 2024, with TONMYA contributing approximately $1.4 million from its launch until year-end [17][19] - Tonix has a robust clinical pipeline, including TNX-4800 for Lyme disease prevention and TNX-102 SL for major depressive disorder, with plans for further development and FDA discussions in 2026 [2][6][9] Commercial Updates - TONMYA was launched on November 17, 2025, and has shown favorable early prescription trends, with cumulative prescriptions totaling approximately 4,200 by February 27, 2026 [4][3] - The company has deployed a salesforce of approximately 90 members to support the commercialization of TONMYA and enhance awareness among healthcare providers and patients [2][4] Financial Highlights - As of December 31, 2025, Tonix had approximately $207.6 million in cash and cash equivalents, a significant increase from $98.8 million in 2024 [13][30] - The company completed a $20.0 million registered direct offering with Point72 in December 2025 to fund commercialization and pipeline development [14] - Research and development expenses for 2025 were approximately $44.5 million, reflecting increased investment in pipeline projects [18] Product Pipeline - TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, is set for FDA discussions regarding Phase 2/3 development in 2026 [6][9] - TNX-102 SL has received IND clearance for a Phase 2 study in major depressive disorder, with enrollment expected to begin in mid-2026 [9][12] - TNX-2900, targeting Prader-Willi syndrome, is planned for a Phase 2 trial initiation in Q1 2027 [11] Operational Highlights - The company has established partnerships for distribution and patient access programs to facilitate the commercialization of TONMYA [8] - Tonix is focusing on expanding payer engagement and establishing contracts with commercial payers while progressing discussions with Medicare and Medicaid [8]

Core Insights - Tonix Pharmaceuticals has launched TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, marking the first new prescription medicine for this condition in over 15 years [2][7] - The drug demonstrated statistically significant pain reduction in Phase 3 trials and was well tolerated by patients [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, addressing high unmet medical needs [8] - The company’s flagship product, TONMYA, is supported by a commercial infrastructure that includes other marketed products for acute migraine [8] Product Details - TONMYA is designed to provide rapid absorption and reduce the formation of the active metabolite norcyclobenzaprine, which can interfere with treatment durability [2][6] - The FDA approved TONMYA in August 2025 based on the results of the Phase 3 RESILIENT trial, which involved 457 patients [2][7] Clinical Trial Results - The Phase 3 RESILIENT trial showed a statistically significant reduction in mean daily pain at 14 weeks, with an increase in the number of patients achieving a 30% reduction in pain compared to placebo [2] - Common adverse events were mild and primarily related to oral cavity reactions, leading to low withdrawal rates from the study [2] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., with a significant majority being women, and is characterized by chronic pain, fatigue, and sleep disturbances [5] - Current FDA-approved treatments for fibromyalgia are limited by side effects and high discontinuation rates, positioning TONMYA as a promising alternative [2][5]

Core Insights - Tonix Pharmaceuticals has launched TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, marking the first new prescription medicine for this condition in over 15 years [2][7] - The drug demonstrated statistically significant pain reduction in Phase 3 trials and was well tolerated by patients [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [8] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, alongside its immunology pipeline [8] Product Details - TONMYA is designed to provide rapid absorption and reduce the formation of the active metabolite norcyclobenzaprine, which can interfere with treatment efficacy [2][6] - The FDA approved TONMYA in August 2025 based on the results of the Phase 3 RESILIENT trial, which involved 457 patients [2][7] Clinical Trial Results - The Phase 3 RESILIENT trial showed a statistically significant reduction in mean daily pain at 14 weeks, with a notable increase in patients achieving a 30% reduction in pain compared to placebo [2] - Common adverse events were mild and primarily related to oral cavity reactions, leading to minimal study withdrawals [2] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain, fatigue, and sleep disturbances [5] - Current FDA-approved treatments for fibromyalgia have limitations related to side effects and adherence, positioning TONMYA as a promising alternative [2][5]

Core Insights - TONMYA is the first FDA-approved treatment for fibromyalgia in over 15 years, providing a novel non-opioid option for patients [1][4] - The drug is now available by prescription nationwide, targeting the estimated 10 million adults in the U.S. suffering from fibromyalgia [2][7] - The approval is based on positive results from two Phase 3 clinical trials, demonstrating significant pain reduction compared to placebo [5][9] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on central nervous system disorders, immunology, and rare diseases [11] - The company operates a state-of-the-art infectious disease research facility and markets treatments for fibromyalgia and acute migraine [11] Product Details - TONMYA (cyclobenzaprine HCl sublingual tablets) is a patented formulation that allows for rapid absorption and is taken once daily at bedtime [8] - The drug targets neurotransmitters involved in fibromyalgia, marking a significant advancement in treatment options for patients [3][4] Clinical Trial Information - The Phase 3 trials, RELIEF and RESILIENT, involved nearly 1,000 patients and showed that TONMYA significantly reduced daily pain scores at 14 weeks [5][9] - A greater percentage of participants experienced a clinically meaningful improvement in pain after three months compared to those on placebo [5] Market Potential - The approval of TONMYA is expected to address the long-standing need for effective treatments in a patient population that has historically faced limited options [2][3] - The patents associated with TONMYA are expected to provide market exclusivity until 2034, with potential extensions until 2044 [8]